1. Generics Bulletin
  2. >>Legal & IP

Former Taro Exec Aprahamian Set To Walk Away From Price-Fixing Charges

Aprahamian Indicted In Feb. 2020 For Alleged Conduct Between 2013 And 2015

 
• By Dean Rudge

The US federal government insisted that it was not against public interest to dismiss an indictment against the former Taro executive Ara Aprahamian, following near four-year-old charges for conspiracy to fix generic prices.

US Department of Justice building, Washington DC (B Christopher/Alamy Stock Photo)
• Source: Shutterstock (Alamy Stock Photo)

The US federal government has requested the dismissal of pending criminal charges against former Taro Pharmaceutical executive Ara Aprahamian, who more than three years ago was accused of generic price-fixing and allocation of customers, in the latest development in the US’s sprawling generic price-fixing saga.

“Dismissal of this case is not contrary to manifest public interest, and it will allow the conservation of this court’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

‘Our Position Has Naturally Shifted’ – How Standalone Sandoz Is Taking On Originator Abuses

 
• By Dave Wallace

As a standalone generics and biosimilars company, Sandoz now feels freer to speak out against originator abuses of intellectual property, the firm’s global IP head Julia Pike tells Generics Bulletin, including challenges to Bayer on rivaroxaban and Amgen on etanercept.

MSN’s Entresto Generic Temporarily Blocked As Key US Patent Expires

 
• By Dean Rudge

The Federal Circuit has temporarily blocked MSN from launching a generic version of Entresto, granting Novartis short-term relief while it reviews the company’s emergency Rule 8 motion for a longer injunction.

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By Dave Wallace

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

The Politics Of Divisionals: How European Patentees Are Still Gaming The System

 
• By Dave Wallace

At Medicines for Europe’s legal affairs conference last month, divisional patents were once again a major subject of discussion. Attendees heard fresh details of how patentee games are preventing generics from hitting the market and restricting wider access to major medicines.

More from Generics Bulletin

ViiV Extends Voluntary License For Long-Acting Cabotegravir As HIV Treatment

 
• By Urtė Fultinavičiūtė

The Medicines Patent Pool’s extended voluntary license to produce long-acting cabotegravir to treat HIV is a win for patients living in LMICs, as the WHO updated its guidance to recommend it as an alternative treatment option.

Krka Passes €1bn Threshold In Just Six Months

 
• By Dean Rudge

Krka has reported its strongest-ever half-year results, surpassing €1bn in sales and growing EBITDA by 8%. Solid performance across most regions, particularly Eastern and Central Europe, supported stable margins and a positive full-year outlook.

ANDA User Fees: Complex Generics, Transparency, Communications Are Early Negotiation Targets

 
• By Sue Sutter

Teva seeks a dedicated development program and first-cycle approval metrics for complex generics. Role of artificial intelligence in the generic drug review process is a talking point for both agency and industry at reauthorization kickoff meeting.